PDB8 WILL IRBESARTAN LEAD TO COST SAVINGS DUE TO DELAYED END STAGE RENAL DISEASE IN HYPERTENSIVE TYPE-2 DIABETICS IN GERMANY?
Nov 1, 2004, 00:00
10.1016/S1098-3015(10)65951-7
https://www.valueinhealthjournal.com/article/S1098-3015(10)65951-7/fulltext
Title :
PDB8 WILL IRBESARTAN LEAD TO COST SAVINGS DUE TO DELAYED END STAGE RENAL DISEASE IN HYPERTENSIVE TYPE-2 DIABETICS IN GERMANY?
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65951-7&doi=10.1016/S1098-3015(10)65951-7
First page :
Section Title :
Open access? :
No
Section Order :
319